The Development Of The AXIS Trial. Gene Therapy To Halt The Retinal Degeneration In Bardet-Biedl Syndrome

Name: The Development Of The AXIS Trial. Gene Therapy To Halt The Retinal Degeneration In Bardet-Biedl Syndrome
Start: 2026-11-12T10:10
End: 2026-11-12T10:30
Location: Novotel London West

Cell 2026 · 12 November 2026 · 10:10–10:30 · Conference Room 3

The Development Of The AXIS Trial. Gene Therapy To Halt The Retinal Degeneration In Bardet-Biedl Syndrome was a session at Cell 2026 on 12 November 2026 in London, with 1 speaker on record.

Speakers

Victor Hernandez — Speaker CSO, Axovia Therapeutics